• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Chronic myeloid leukemia following liver transplantation: A case report.肝移植后慢性髓系白血病：一例报告。
Mol Clin Oncol. 2017 Dec;7(6):1159-1161. doi: 10.3892/mco.2017.1465. Epub 2017 Oct 20.
2
Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant.慢性髓性白血病的治疗选择：伊马替尼对比干扰素对比异基因移植。
Curr Opin Oncol. 2004 Mar;16(2):95-9. doi: 10.1097/00001622-200403000-00002.
3
Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report.伊马替尼致慢性髓性白血病暴发性肝衰竭：肝移植及第二代酪氨酸激酶抑制剂的作用：一例报告
J Med Case Rep. 2018 Mar 10;12(1):63. doi: 10.1186/s13256-018-1588-0.
4
Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.甲磺酸伊马替尼（STI571）用于费城染色体阳性急性白血病患者异基因造血干细胞移植和供体淋巴细胞输注的预处理。
Leukemia. 2003 Feb;17(2):290-7. doi: 10.1038/sj.leu.2402808.
5
Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).突尼斯慢性髓性白血病患者：伊马替尼时代的流行病学与预后（一项多中心研究经验）
Ann Hematol. 2018 Apr;97(4):597-604. doi: 10.1007/s00277-017-3224-2. Epub 2018 Jan 6.
6
Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.对接受甲磺酸伊马替尼（格列卫）治疗的异基因移植后慢性髓性白血病复发患者进行长期随访：持久的细胞遗传学缓解以及转化为完全供体嵌合状态且无移植物抗宿主病。
Clin Cancer Res. 2004 Aug 1;10(15):5065-71. doi: 10.1158/1078-0432.CCR-03-0580.
7
Successful Treatment of Chronic Myeloid Leukemia With Dasatinib After Kidney Transplantation: A Case Report.肾移植后使用达沙替尼成功治疗慢性髓性白血病：病例报告
Transplant Proc. 2020 Mar;52(2):600-603. doi: 10.1016/j.transproceed.2019.06.006. Epub 2019 Nov 14.
8
Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.撒哈拉以南非洲地区伊马替尼时代慢性髓性白血病的模式。
Ann Hematol. 2016 Oct;95(10):1603-10. doi: 10.1007/s00277-016-2745-4. Epub 2016 Jul 1.
9
Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation.在接受异基因移植后复发且接受伊马替尼（STI571）成功治疗的Ph+慢性髓性白血病患者的供体来源Ph-细胞中检测到8号染色体三体。
Leuk Lymphoma. 2004 Jul;45(7):1453-8. doi: 10.1080/10428190410001670637.
10
Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.达沙替尼：从治疗对伊马替尼耐药或不耐受的慢性髓性白血病患者到治疗新诊断的慢性期慢性髓性白血病患者。
Clin Ther. 2012 Feb;34(2):272-81. doi: 10.1016/j.clinthera.2012.01.009. Epub 2012 Jan 27.

本文引用的文献

1
Subsequent malignancies after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后的继发恶性肿瘤
Clin Transplant. 2017 Jul;31(7). doi: 10.1111/ctr.12987. Epub 2017 May 25.
2
Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors.酪氨酸激酶抑制剂治疗慢性髓性白血病期间第二原发性恶性肿瘤的发生率
Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):577-581. doi: 10.1016/j.clml.2016.06.010. Epub 2016 Jun 8.
3
A case report of acute myeloid leukemia after liver transplantation.肝移植后急性髓系白血病 1 例报告
Acta Haematol. 2013;129(4):225-8. doi: 10.1159/000345412. Epub 2013 Jan 5.
4
T-cell acute lymphoblastic leukaemia after liver transplantation: post-transplant lymphoproliferative disorder or coincidental de novo leukaemia?肝移植后 T 细胞急性淋巴细胞白血病：移植后淋巴组织增生性疾病还是偶发的新发白血病？
Hematol Oncol. 2013 Mar;31(1):49-53. doi: 10.1002/hon.2016. Epub 2012 May 22.
5
BCR-ABL positive cells and chronic myeloid leukemia in immune suppressed organ transplant recipients.免疫抑制器官移植受者中的 BCR-ABL 阳性细胞和慢性髓性白血病。
Eur J Haematol. 2010 Jan 1;84(1):26-33. doi: 10.1111/j.1600-0609.2009.01357.x. Epub 2009 Oct 3.
6
Acute leukemia, a rare but fatal complication after liver transplantation.急性白血病是肝移植术后一种罕见但致命的并发症。
Leuk Res. 2009 Oct;33(10):1349-51. doi: 10.1016/j.leukres.2009.03.035. Epub 2009 May 15.
7
Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cells.新型肌苷5-单磷酸脱氢酶抑制剂AVN944对前列腺癌细胞的抗增殖作用。
Int J Cancer. 2008 Nov 15;123(10):2294-302. doi: 10.1002/ijc.23788.
8
Two cases of post-liver transplant acute myeloid leukemia in Korean adults: review of bibliographies and comparison with post-renal transplant acute myeloid leukemia.
Ann Hematol. 2008 Jun;87(6):513-4. doi: 10.1007/s00277-008-0458-z. Epub 2008 Feb 26.
9
[Imatinib-induced toxic hepatitis: description of two cases and review of the literature].[伊马替尼诱导的中毒性肝炎：两例病例描述及文献复习]
Gastroenterol Hepatol. 2007 Nov;30(9):525-30. doi: 10.1157/13111687.
10
Chronic myeloid leukemia after living donor liver transplantation.
Transplantation. 2007 Jun 15;83(11):1521-2. doi: 10.1097/01.tp.0000265587.17307.6a.

肝移植后慢性髓系白血病：一例报告。

Chronic myeloid leukemia following liver transplantation: A case report.

作者信息

Zhang Ling, Long Bing, Li Xiao-Qing, Fang Zhi-Gang, Lai Wen-Xing, Lin Dong-Jun

机构信息

Department of Hematology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, P.R. China.

出版信息

Mol Clin Oncol. 2017 Dec;7(6):1159-1161. doi: 10.3892/mco.2017.1465. Epub 2017 Oct 20.

DOI:10.3892/mco.2017.1465
PMID:29285393
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5740856/
Abstract

Long-term utilization of immunosuppression in organ transplant recipients leads to decreased immune-mediated tumor surveillance and increased risk of developing malignant tumors. However, chronic myeloid leukemia (CML) following living donor liver transplantation (LDLT) is rarely reported. The current case report presents a 42-year-old male patient who developed CML 14 months following LDLT. The patient achieved complete hematologic remission and early molecular response at 3 months imatinib treatment and major molecular response at 12 months imatinib treatment. The pathogenesis, risk factors, treatment and prognosis for CML following liver transplantation are unclear. Therefore, further analysis through accumulation of cases will be of great importance to prevent and treat this rare complication following liver transplantation.

摘要

器官移植受者长期使用免疫抑制剂会导致免疫介导的肿瘤监测功能下降，患恶性肿瘤的风险增加。然而，活体供肝肝移植（LDLT）后发生慢性髓性白血病（CML）的情况鲜有报道。本病例报告介绍了一名42岁男性患者，他在LDLT后14个月发生了CML。该患者在接受伊马替尼治疗3个月时达到完全血液学缓解和早期分子反应，在接受伊马替尼治疗12个月时达到主要分子反应。肝移植后CML的发病机制、危险因素、治疗及预后尚不清楚。因此，通过积累病例进行进一步分析对于预防和治疗肝移植后这种罕见的并发症至关重要。